Background The development of more eff ective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenström's macroglobulinaemia. The aim of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and relapsed Waldenström's macroglobulinaemia.
Introduction
Waldenström's macroglobulinaemia is a type of indolent B-cell non-Hodgkin lymphoma characterised by production of a monoclonal IgM paraprotein, bone marrow infi ltration, and variable expression of CD20. [1] [2] [3] Patients have cytopenias resulting from bone marrow infi ltration and complications arising from high serum concentrations of IgM such as hyperviscosity, haemolytic anaemia, and cryoglobulinemia. [4] [5] [6] [7] [8] Until recently, no treatments were specifi cally approved for Waldenström's macroglobulinaemia; in January, 2015, the US Food and Drug Administration approved ibrutinib for patients with this disease, however, some patients are unable to tolerate ibrutinib because of adverse events such as diarrhoea, bleeding risk, hypertension, arthralgias, and atrial fi brillation. Additionally, not all patients achieve adequate responses. Other drugs that are used, including alkylators and nucleoside analogues, cause myelosuppression and long-term marrow failure. 25% to 75% of patients with Waldenström's macroglobulinaemia achieve an overall response with the chimeric anti-CD20 monoclonal antibody rituximab, [9] [10] [11] [12] [13] [14] with a median time to progression of 6-16 months; [9] [10] [11] 14 however, 40-50% of patients treated with rituximab monotherapy have an IgM fl are, defi ned as a transient increase in IgM that occurs with therapy and is followed by a suffi cient decrease in IgM to qualify as a response. The acute rise in IgM is often suffi cient to result in signifi cant morbidity and mortality; 1, 14, 15 thus, development of new treatments that do not cause such fl are, especially non-chemotherapeutics, is needed for patients with Waldenström's macro globulinaemia.
Ofatumumab is a human anti-CD20 monoclonal antibody that binds to an epitope distinct from that which rituximab binds to. 16 Ofatumumab has more potent complement-dependent cytotoxicity than rituximab in vitro, especially in cells with low CD20 expression such as chronic lymphocytic leukaemia. 17, 18 Ofatumumab is approved for the treatment of chronic lymphocytic leukaemia that is refractory to fl udarabine and alemtuzumab 19, 20 and for previously untreated chronic lympho cytic leukaemia in combination with chlorambucil, 21 and has shown clinical activity in patients with B-cell non-Hodgkin lymphoma. 22 Considering the established antitumour eff ects of rituximab, variable CD20 expression in Waldenström's macroglobulinaemia, and the enhanced complement-dependent cytotoxicity of ofatumumab, we did a phase 2 clinical trial to assess ofatumumab effi cacy and tolerability in patients with Waldenström's macroglobulinaemia.
Methods

Study design and patients
We did a phase 2, open-label, single-arm study at six centres (hospitals and cancer clinics) in the USA (CA, NY, MN, and OH; appendix). Institutional review boards at participating centres approved the protocol; this study was done by the Waterfall Waldenström's Research Consortium and other centres.
Adult patients (≥18 years) with Waldenström's macroglobulinaemia, an Eastern Cooperative Oncology Group performance status of 2 or less, and life expectancy of more than 6 months were eligible. Patients had to have untreated or relapsed Waldenström's macroglobulinaemia, and require therapy according to criteria established by the Second International Workshop on Waldenström's macro globulinaemia. 8, 23, 24 Other inclusion criteria were: detectable CD20-positive tumour by immunohisto-chemistry or fl ow cytometry; adequate organ function defi ned by an absolute neutrophil count of 1·0 × 10 9 cells per L or more and a platelet count of more than 50 × 10 9 platelets per L unless due to marrow infi ltration; transaminase concentrations of at least 2·5 times the upper level of normal (ULN); total bilirubin less than two times the ULN unless due to Gilbert's disease; and serum creatinine less than 265·2 μmol/L. Patients with monoclonal antibody therapy within 3 months before enrolment, other treatment for Waldenström's macroglobulinaemia within 28 days before enrolment, or uncontrolled chronic or active infections, HIV-positivity, or positive serology for
Research in context
Evidence before this study We searched PubMed for relevant English-language publications using the terms "Waldenström's treatment", "rituximab", "ofatumumab", "IgM fl are", "rituximab mechanism of action", and "CD20 ligation", with no date restrictions. In January, 2015, the US Food and Drug Administration approved ibrutinib for patients with Waldenström's macroglobulinaemia; however, some patients are unable to tolerate ibrutinib because of adverse events such as diarrhoea, bleeding risk, hypertension, arthralgias, and atrial fi brillation. Additionally, not all patients achieve adequate responses. Alternative treatment options include alkylators and nucleoside analogues; however, these cause myelosuppression and long-term marrow failure. The chimeric anti-CD20 monoclonal antibody rituximab is clinically active in Waldenström's macroglobulinaemia (25% to 75% of patients treated with rituximab monotherapy had a response) but 40% to 50% of patients developed an IgM fl are. Thus, development of new treatments, especially non-chemotherapeutics, is needed for patients with Waldenström's macroglobulinaemia.
Added value of this study
The results of our phase 2, open-label, single-arm study showed that ofatumumab monotherapy had clinical activity in Waldenström's macroglobulinaemia, including patients with a high tumour burden, and a manageable safety profi le. The results compared favourably with those of rituximab and the incidence of IgM fl are with ofatumumab (in two [9%] of 22 patients) was lower than previously reported for rituximab (40-50%). Re-treating patients who had initially responded to ofatumumab but later progressed, resulted in responses in most cases. hepatitis B or C were excluded from the study. The 3-month exclusion for monoclonal antibody therapy is based upon the potential for responses to be noted in patients with Waldenström's macroglobulinaemia beyond the 3-month time point. Patients were recruited from physician practices at participating centres. Patients gave written informed consent.
Implications of all the available evidence
Procedures
Patients received up to three cycles (cycle 1, redosing cycle, and cycle 2) of weekly ofatumumab (appendix). For cycle 1 we allocated patients into one of two treatment groups based on the timing of their enrolment and a protocol amendment made on Dec 9, 2009. Patients in treatment Group A received intravenous ofatumumab at 300 mg during week 1 and 1000 mg during weeks 2-4. Because of the acceptable safety of the 1000 mg dose in treatment group A and clinical activity of the 2000 mg dose established in chronic lymphocytic leukaemia, the study was amended to change cycle 1 for treatment group B who received ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5. We premedicated patients with paracetamol 1000 mg (or 975 mg) orally, diphenhydramine 50 mg orally or intravenously, and dexamethasone 8 mg orally or intravenously.
Responses were assessed centrally starting at week 8 of cycle 1, given the potential of IgM fl are and the long time to response with rituximab. Patients with stable disease or a minor response at week 16 of cycle 1 were eligible to receive a redosing cycle of ofatumumab at 300 mg during week 1 and 2000 mg during weeks 2-5 of the cycle. Patients with progressive disease came off study and did not received further study drugs. We reassessed responses at week 16 of the redosing cycle. Patients who achieved a response after cycle 1 or the redosing cycle and subsequently developed progressive disease within 36 months were eligible to receive cycle 2 of ofatumumab at 300 mg during week 1 and 2000 mg during weeks 2-5. No dose reductions were permitted during the study; if a patient experienced a treatment-related adverse event of grade 3 or 4 during treatment that did not resolve by the next scheduled dose, the next dose was held until the adverse event had resolved to grade 1 or better. If the adverse event did not suffi ciently improve after 2 weeks, the patient was removed from treatment. Patients could be withdrawn from study participation for disease progression or initiation of alternative therapy, on the advice of the investigator, at the request of the patient, or if they were lost to follow-up or died.
The rationale for having a redosing cycle was to assess whether a second cycle of ofatumumab would be able to improve the response of a patient who was a poor responder or non-responder. Because the dosing of monoclonal antibodies is arbitrary, we felt it was important to include the responses at the diff erent intervals to provide evidence of a dose eff ect. The rationale for having cycle 2 was to assess whether retreatment with ofatumumab would be able to generate responses in patients who previously showed a response and then progressed. Patients were required to wait until they at least showed progression as they would need to meet standard criteria for needing further treatment. Patients were required to meet at least one of the following criteria to be considered as requiring therapy in cycle 2: rising IgM, haemoglobin concentration of 100 g/L or less, platelet count of 100 × 10 9 platelets per L or less, symptomatic or bulky lymphadenopathy or organomegaly, or systemic manifestations of Waldenström's macroglobulinaemia, including hyperviscosity, neuropathy, amyloidosis, cryoglobulinaemia, and B symptoms.
We obtained blood samples during and after each treatment cycle. For each infusion, the maximum observed plasma ofatumumab concentration (C max ) and the plasma ofatumumab concentration before the start of the next infusion (C trough ) were determined directly from the raw concentration-time data.
Outcomes
We used National Cancer Institute Common Terminology Criteria for Adverse Events, v.3.0 to asssess toxicity from the fi rst dose until 60 days after the last treatment dose. Patients were assessed for the primary endpoint of overall response (ie, best overall response irrespective of when it occurred) centrally using recommendations from the second and third international workshops on Waldenström's macroglobulinaemia. 25, 26 Response criteria were: complete response (complete disappearance of monoclonal protein by immunofi xation and lympha denopathy or Data are median (range) or n (%) unless otherwise stated. Treatment group A=ofatumumab 300 mg during week 1 of the treatment cycle followed by 1000 mg during weeks 2-4. Treatment group B=ofatumumab 300 mg during week 1 of the treatment cycle followed by 2000 mg during weeks 2-5. *Includes only previously treated patients. organo-megaly confi rmed at least 6 weeks later); partial response (>50% reduction in monoclonal protein and lympha-denopathy or organomegaly with no new signs or symptoms of disease); minor response (>25% but <50% reduction in serum monoclonal protein with no new signs or symptoms of disease); stable disease (<25% reduction and <25% increase in serum monoclonal protein without progression of lymphadenopathy or organomegaly or new signs or symptoms of disease); progressive disease (>25% increase in serum monoclonal protein confi rmed by a second measurement or progression of clinically signifi cant fi ndings attributable to Waldenström's macroglobulinaemia). Overall response consisted of the number of patients who achieved a complete response, partial response, and minor response divided by the number of patients enrolled on to the study. We did baseline CT scans within 6 weeks of the fi rst dose of cycle 1. CT scans were also required for patients whose initial response to ofatumumab treatment was progressive disease based on progressive lymphadenopathy (done at the time that the criteria for progressive disease were met) and for patients with measurable disease on their baseline CT scan whose IgM concentrations indicated complete response or partial response (at the time of response). The baseline IgM (average of screening and cycle 1, week 1 IgM concentrations) was used to assess response and results were reviewed centrally. IgM was measured weekly until week 8 of all cycles, then monthly for the fi rst year. IgM fl are was defi ned as IgM concentrations increasing by more than 25% from baseline and associated with a response to treatment. Secondary endpoints were time to response (defi ned as the time from baseline date to the fi rst response date), duration of response (defi ned as the time from the initial response to relapse or progression, or death), time to relapse for complete responders (defi ned as the time from initial complete response to relapse or death), time to progression for partial or minor responders (defi ned as the time from the initial partial or minor response to progression or death), overall survival (defi ned as time from baseline date until death of any cause), and progression-free survival (defi ned as the time from baseline date to disease progression or death). Laboratory monitoring of haematology and chemistry were done weekly through week 8, then every 4 weeks through week 48, then every 12 weeks for the duration of the study.
Statistical analysis
This was an exploratory study with no formal hypothesis testing planned. For an expected 55% of patients (a similar proportion to those treated with rituximab) to achieve an overall response, the CI boundaries for the overall response were deemed to be 38%-72%. Responders included patients with complete response, partial response, or minor response. Patients with stable disease, progressive disease, or unknown or missing responses were considered non-responders.
The primary safety and effi cacy population was the intention-to-treat (ITT) population which included all patients deemed eligible for treatment and who were exposed to ofatumumab irrespective of the planned course of treatment. Non-evaluable patients were those with insuffi cient data or insuffi cient time from treatment for a determination of response to be made at a given visit.
For the primary endpoint, we estimated and presented the proportion of patients with an overall response and corresponding exact 95% CI after cycle 1 and the redosing cycle in the ITT population. We generated summary statistics for the secondary endpoints. Progression-free survival, time to response, and duration of response were estimated using the KaplanMeier method with day 0 defi ned as the date of the fi rst infusion. Progression-free survival estimates did not include the interval following disease progression for patients who received cycle 2.
For the pharmacokinetics analyses, we did non-linear mixed eff ects modelling of the concentration-time data using a two-compartment model with fi rst-order elimination and combined additive and proportional error using the software NONMEM, v.7.2.0. The covariate model was adapted from the population pharmacokinetic model for ofatumumab monotherapy. 27 Individual post-hoc parameter estimates were generated for each patient, and pharmacokinetic parameter estimates were derived using standard equations. A data monitoring committee did not oversee the study. This study is registered at ClinicalTrials.gov (NCT00811733). 
Role of the funding source
The funder of the study had a role in study design, data collection, data analysis, data interpretation, and writing of the report. All authors approved the manuscript for submission. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between March 17, 2009 , and Feb 24, 2011, we enrolled and assigned 37 patients to treatment (15 in treatment group A and 22 in treatment group B; baseline characteristics in table 1). All 37 patients were included in the effi cacy and safety analysis. 26 (70%) of 37 patients had a haemoglobin concentration of less than 110 g/L. 28 (76%) of 37 had been previously treated, with a median of three previous therapies (range [1] [2] [3] [4] [5] , of whom 25 (89%) of 28 had received previous rituximab. Two patients (one in each group) discontinued cycle 1 early because of adverse events (one had haemolysis, the other had fl uid overload), and one patient in treatment group B withdrew consent (fi gure 1). No data were obtained regarding plasmapheresis and symptomatic hyperviscosity before protocol enrolment.
All patients assessed for the primary endpoint were assessed for response, with a median duration follow-up of 405 days (IQR 142-743) for group A, 393 days (294-466) for group B. In patients who had a minor response or better, the median follow-up time was 743 days (670-799) for those in group A, and 414 days (345-484) for those in group B. In patients with a baseline IgM concentration of less than 4 g/dL, more than half responded to ofatumumab (table 2) . 19 (51%, 95% CI 34·4-68·1) of 37 patients achieved an overall response after cycle 1 (table 3). 12 patients (32%, eight in treatment group A and four in treatment group B) entered the redosing cycle after cycle 1 (only patients with minor response or stable disease were eligible, and some patients chose not to receive retreatment). The median IgM concentration at the time of redosing was 3·2 g/dL (group A: 3·2 g/dL; group B: 4·0 g/dL). Ten patients (83% ) had response assessments during the redosing cycle, three (25%) of whom improved in response status (one stable disease to minor response [time to redosing 216 days, no progression], one stable disease to partial response [time to redosing 183 days, time to progression 558 days], and one minor response to partial response [time to redosing 279 days, patient did not progress]). The remaining two patients (of 12 who entered redosing but who did not have response assessments) withdrew from the study and did not have visits with response assessments for the redosing period.
After cycle 1 and the redosing cycle, 22 (59%, 42·1-75·2) of 37 patients had achieved an overall response (table 3). 13 patients entered and received treatment cycle 2. The median IgM at the time of cycle 2 was 2·1 g/dL (group A: 1·7 g/dL; group B: 2·4 g/dL). Ten (77%) of 13 patients achieved an overall response after cycle 2 (group A: four [80%] of fi ve, group B: six [75%] of eight), with six partial responses and four minor responses. Median time to response for the 13 patients in cycle 2 was 85 days (95% CI 78-153). Of these 13 patients, two had received redosing (group unknown).
The IgM concentrations at cycle 2 were 1·9 g/dL (value at nadir 1·0) and 1·7 g/dL (value at nadir 0·27). For all patients, the median change in IgM from baseline to nadir was -39·8% (fi gure 2, table 3). Median change was -44% in group A (n=15) and -39% in group B (n=22).
Of seven patients who had an enlarged spleen at baseline, fi ve had a normal-sized spleen post-baseline, one spleen remained enlarged, and one patient did not have a postbaseline assessment of their spleen. One patient had an enlarged liver at baseline, which was normal post-baseline.
Median haemoglobin concentration was 98 g/L (range 53-132) at screening and increased to 115 g/L at month 3, 120 g/L at month 6, and 127 g/L at month 12. Of 26 patients who had a baseline haemoglobin
Figure 2: Changes in IgM concentration
Data are changes from baseline to nadir for patients in cycle 1 plus redosing cycle for all patients (n=37). Treatment group A: in cycle 1, patients were administered ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2-4. Treatment group B: in cycle 1, patients were administered ofatumumab 300 mg during week 1 followed by 2000 mg during weeks 2-5. Six (16%) of 37 patients had a haematological toxicity (two grade 1, three grade 3, one grade 4), four (11%) of 37 deemed drug-related. One patient (3%) of 37 had grade 3 neutropenia that was deemed drug-related. One (2%) of 37 patients had grade 3 Coombs-negative haemolysis, and one (2%) of 37 developed grade 3 Coombs-positive haemolysis. No adverse events due to other cytopenias were reported.
12 patients reported serious adverse events; haemolysis and pyrexia were the most common (each occurring in two [5%] of 37 patients). Three patients (8%) discontinued treatment because of adverse events (acute renal failure [n=1] and haemolysis [n=2]). No deaths had occurred by the end of this study.
Two (9%) of 22 responding patients, both in group B, met the protocol defi nition of an IgM fl are. In these patients (baseline IgM: 4·34 and 1·14 g/dL, respectively), IgM concentration rose by 79% and 240%, peaking at day 42 and day 37, before achieving a response at day 356 and day 93, respectively. One of these patients was rituximab-naive, and the second had received previous rituximab treatment. In group A, geometric mean clearance and half-life values were 27·9 mL/h and 10·9 days, compared with 13·5 mL/h and 23·9 days, respectively in group B (table 5).
Discussion
Our fi ndings suggest that ofatumumab is well tolerated, with signifi cant clinical activity in untreated and relapsed Waldenström's macroglobulinaemia. As monotherapy, ofatumumab's activity in Waldenström's macroglobulinaemia is highly promising, especially in patients with a high tumour burden (IgM ≥4 g/dL), half of whom achieved an overall response. Published results of rituximab 11 in similar patients reported that 18% achieved an overall response. This fi nding can have a major clinical impact and warrants further assessment because the response rate and low risk of IgM fl are extends potential non-chemotherapeutic treatment options for patients with high IgM concentrations for whom current practice typically requires chemotherapy to avoid IgM fl ares. Improvement in haemoglobin concentrations is an important goal of treatment, as many patients with Waldenström's macroglobulinaemia have substantial anaemia, and baseline haemoglobin concentrations of 115 g/L or less correlate with a poor prognosis in these patients. 28 We noted that ofatumumab treatment improved haemoglobin concentrations, with some patients achieving a signifi cant increase (≥30 g/L) in haemoglobin or resolution of anaemia. The prolonged On the basis of the safety profi le of the 1000 mg dose in group A, the approval and safety data of the 2000 mg dose in chronic lymphocytic leukaemia, and lower expression of CD20 in Waldenström's macroglobulinaemia and the likely benefi t of higher doses with lower CD20 expression, we revised the study to administer a higher dose of ofatumumab in group B. Although we could not make a statistical comparison between fi ndings from group A and group B because of the small sample size and non-randomised treatment assignment, the higher dose seemed to improve clinical outcomes. Previous therapy correlated with a lower overall response in group A but did not aff ect the probability of response in group B. Similarly, previous rituximab exposure correlated with a lower overall response in group A but not in group B. Additionally, 17% of patients in group A with an IgM of at least 40 g/L achieved an overall response, compared with 83% in group B. These fi ndings suggest that the 2000 mg dose of ofatumumab might be more eff ective in patients with Waldenström's macro globulinaemia, and could negate adverse prognostic factors such as IgM of at least 40 g/L, previous therapy, and anaemia.
We could not draw any conclusions regarding the effi cacy and tolerability of ofatumumab compared with rituximab because we did not obtain information on the outcome and tolerability of previous rituximab treatments, and because of the diffi culties in comparing across two separate phase 2 studies. Similarly, we did not assess the eff ect of FCGR3A polymorphisms and MYD88 and CXCR4 mutations on response, preventing any conclusion regarding diff erences in mechanism of action between these two anti-CD20 monoclonal antibodies.
Patients in group A had higher ofatumumab clearance and shorter half-life values than patients in group B, although no statistical comparison was made. Since binding to B cells is a clearance mechanism for ofatumumab, these results suggest that the higher dosing regimen might have decreased the tumour cell burden more on average in group B, which is consistent with the clinical results. The pharmacokinetic parameter values in group B were similar to those in patients with chronic lymphocytic leukaemia; combined data from three clinical trials in patients with chronic lymphocytic leukaemia, geometric mean values of clearance and half-life were 12·9 mL/h and 15·6 days, respectively. 29 Ten (77%) of 13 patients who responded to ofatumumab and subsequently had progressive disease responded to retreatment with ofatumumab (six partial responses, four minor responses), suggesting that patients with Waldenström's macroglobulinaemia who respond to ofatumumab might derive clinical benefi t from retreatment at subsequent progression.
Ofatumumab was well tolerated in this study, and the adverse event profi le was consistent with observations from other ofatumumab studies in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The most common adverse events were grade 1-2 infusion reactions and infections, none of which resulted in patient withdrawal. Three patients discontinued therapy due to serious adverse events; one patient, with a baseline IgM concentration of 6·6 g/dL, developed acute renal failure requiring plasmapheresis, and two patients experienced haemolysis. non-randomised nature of this study and the absence of a standardised defi nition across studies. Additionally, the frequency of IgM monitoring and previous exposure to rituximab might also be factors for diff erence in rituximab versus ofatumumab fl are rates.
In this study, the median time to response for cycle 1 plus redosing cycle was 78·5 days; the median time to IgM nadir, or best response, was 298 days; and the median time to normalisation of haemoglobin was 20·9 weeks. These fi ndings indicate that response to ofatumumab in Waldenström's macroglobulinaemia is a prolonged process, supporting the hypothesis that the therapy kills a compartment of malignant lymphocytes that probably diff erentiate into the IgM-secreting cells, which die at a standard rate.
In summary, ofatumumab monotherapy had signifi cant clinical benefi t with an acceptable toxicity profi le in patients with Waldenström's macroglobulinaemia. A higher dose of ofatumumab might have contributed to a higher number of patients who had high serum IgM or previous rituximabbased therapy achieving a response. However, the small sample size and the use of the higher dosing regimen for the redosing cycle and cycle 2 in all patients preclude a defi nitive conclusion about the optimum ofatumumab dosing regimen in Waldenström's macroglobulinaemia. Additionally, because of short follow-up, data are not available regarding whether dosing might aff ect response duration or progression-free survival.
Immunotherapy off ers the potential of clinical effi cacy without the marrow toxicity of cytotoxic chemotherapy. Because Waldenström's macroglobulinaemia is an indolent lymphoma in which progression-free survival is the most clinically meaningful endpoint, longer follow-up with updated data will further support the durability of responses and the clinical effi cacy of ofatumumab in Waldenström's macroglobulinaemia.
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